Correlation of ER, PR and HER-2/Neu with other Prognostic Factors in Infiltrating Ductal Carcinoma of Breast

Document Type: Original Research

Authors

1 Dept. of Pathology, Babol University of Medical Sciences, Babol, Iran

2 Dept. of Surgery, Babol University of Medical Sciences, Babol, Iran

3 Dept. of Radiology, Babol University of Medical Sciences, Babol, Iran

10.7508/ijp.2015.03.007

Abstract

Background and Objectives: Breast cancer is the most common malignancy among women in the world. The aim of this study was to assess estrogen receptor (ER), progesterone receptor (PR) and HER-2/neu of infiltrating ductal carcinoma (IDC) with tumor size, histologic grade, lymph node metastasis and age. Methods: This study was carried out on 300 tissue blocks ofpatients with IDC who underwent mastectomy from 2007 to 2011 in Shahid Beheshti Hospital, affiliated to Babol University of Medical Sciences, Babol, Iran. Data including age, tumor size, and histologic grade and lymph node status retrieved from pathology department. Result: Themean age of the patients was 40.2±2.3 (ranged 19-82 years). ER and PR were positively correlated with each other (P= 0.001) and they inversely correlated with HER-2/neu  (P=0.001). We observed correlation between ER and PR expression and low histologic grade (P= 0.001) and HER-2/neu expression and high histologic grade (P= 0.003). There was correlation between HER-2/neu expression and lymph node involvement (P=0.03). None of these makers showed correlation with age and tumor size (P> 0.05). Conclusion: Our findings indicate the importance of ER, PR and HER-2/neu expression as prognostic factors for therapeutic decision.   How to cite this article: Siadati S, Sharbatdaran M, Nikbakhsh N, Ghaemian N. Correlation of ER, PR and HER-2/Neu with other Prognostic Factors in Infiltrating Ductal Carcinoma of Breast. Iran J Pathol. 2015;10(3):221-6.

Keywords


Introduction

Breast cancer is the most common malignancy and the leading cause of cancer related death among women all around the world (1, 2). In Iran, it is the most common cancer among women and affects them one decade earlier than women in western countries (3, 4). Besides, the prevalence of early stages among Iranian women is extremely low (5).

Factors including tumors size, histologic grade, lymph node metastasis and hormone receptor status used to estimate prognosis (6-8). Evaluation of prognostic factors including biomackers is highly recommended for the best management and therapeutic decision of breast cancer patients (9).

Among these biomarkers, estrogen receptor (ER), progesterone receptor (PR), and HER-2 / neu are mostly used for assessment of breast cancer. Her-2/neu protooncogen (erbB-2) encodes a 185 kDa transmembrane phosphoglycoprotein with tyrosine kinase activity. It is standard practice to determine both estrogen and progesterone receptor status at the time of diagnosis for definitive surgical therapy (10). HER-2/neu encodes a tyrosine kinase related to epidermal growth factor. Several studies revealed HER-2/neu overexpression as an indicator for low response to tamoxifen and decreased survival (8,10,11). Tumors with negative immunohistochemistry (IHC) staining for ER,PR and HER-2/neu were high grade and mostly seen in women older than 50 (12).

This study was performed to assess the possible correlation between expression of ER,PR and HER-2/neu with other prognostic factors like tumor size, histologic grade, lymph node metastasis and age.

 

Materials and Methods

The present cross-sectional study was conducted on 300 paraffin blocks of patients, who underwent mastectomy and diagnosed with infiltrating ductal carcinoma (IDC) in Shahid Beheshti Hospital, Babol, northern Iran from 2007 to 2012. Data including age, tumor size and grade and lymph node status were retrieved from the files of patients in pathology department.

Patients were divided into two age groups: 1) < 50 years and 2) ≥50 years. Furthermore, tumor size was divided to 1) ≤2 cm and 2)>2 cm. Bloom-Richardson scoring was used for histologic grading (grade I, II and III).

In brief, paraffin- embedded blocks were used to prepare 3 µm thick slides, then sections were deparaffinized in xylene and rehydrated through graded concentration of ethanol. For antigen retrieval, the slides were incubated with Tris-EDTA (PH=9) for 15 minutes in microwave. After washing with Tris-buffer saline (TBS) and tap water, all slides were incubated in H202-methanol solution (1/9) for 10 minutes to inhibit endogenous proxidases. At the next step, the slides were covered by primary antibody (Dako, Denmark) for 30 minutes at room temperature, followed by incubation with Envision. Then, all slides were covered by chromogen and Di amino Benzidine. ER, PR and HER2/neu were semi-quantitatively evaluated. H score was used for ER and PR (a negative result was defined as a score of ≤ 50, and positive between 51 and 300). The DAKO scoring system for HER-2/neu was defined as negative for scores of 0,1+, or 2+ and positive for tumors with a score of 3+(10,11)(Fig. 1-3).

Quantitative values of the data were presented as mean ±SD. A Chi-square test and t-test were used to determine statistical analysis using SPSS software version 20 for windows  (Chicago, Illinois, USA). A P-value of < 0.05 was considered as significant level.

Immunohistochemical staining showed positivity for ER

Fig.1: Immunohistochemical staining showed positivity for ER

Immunohistochemical staining showed positivity for HER2/neu

Fig.2: Immunohistochemical staining showed positivity for HER2/neu

Immunohistochemical staining showed positivity for PR

Fig.3: Immunohistochemical staining showed positivity for PR

Results

This study was performed on 300 paraffin tissue blocks of patients with IDC. The mean age of patients was 40.2±2.3 with range of 19 to 82 years. Patients aged 35 to 45 years were the most frequent age group, 102 cases (34%). Most of tumors, 242 cases (80.6%) belonged to histologic grade II. The tumor size ranged from 0.5 cm to 16 cm with a mean range of 3.15±2.52 cm. The average of lymph node involvement was 4.5±3.4. Of the 300 patients 85.7% (n= 257) had lymph node metastasis. Table 1 reveals the clinical characteristics of all 300 women with IDC.

ER and PR were positively correlated with each other (P=0.001). HER-2/neu was inversely related to ER and PR expression (P=0.0001). We demonstrated statistically significant correlation between HER-2/neu expression and lymph node metastasis (P=0.03). However, this correlation was not found for ER and PR. Statistically significant correlation was observed between ER and PR expression and histologic grade I and II (P= 0.001). On the other hand, significant correlation between HER-2/neu expression and histologic grade III was found (P= 0.003). The expression of these biomarkers had no significant correlation with age and tumor size (P>0.05).

 

Table 1: Clinical characteristics (n= 300)

Variable

 N

%

Age(years)

<50

≥50

 

220

80

 

73.33

26.66

Tumor size(cm)

≤2

>2

 

125

175

 

41.66

58.33

Tumor grade

I

II

III

 

28

242

30

 

9.33

80.66

10.00

Lymph node

Negative

positive

 

43

257

 

14.33

85.66

Discussion

The present study was conducted on 300 patients with IDC. In Iran, this is the first time that one investigates the correlation between ER, PR and HER-2/neu with some prognostic factors on large population of patients with IDC.

In the current study, the mean age of the patients was 40.2±2.3 that was lower than other studies from Iran (1, 7, 13). It shows that in the recent years younger women have been diagnosed with breast cancer. This fact may be explained by different factors that simply go beyond the scope of this study and must be investigated in future.

We observed a significant correlation between histologic grade I and II and expression of ER and PR that is similar to the results of other studies (7, 12). Our study, as well as others, found a significant correlation between HER-2/neu expression and histologic grade III (10, 14, 15). Her-2/neu is an epidermal growth factor on the surface of a cell that transmits growth signals to the cell nucleus. Overexpression of the receptor is associated with poor prognosis. This may be more of a reflection of the biologic correlates of Her-2/neu overexpression that an independent prognostic indicator. Regarding sample size it seems that HER-2-neu expression is associated with poor prognosis while ER and PR expression are indicators of response to hormone therapy and better prognosis. Although hormone receptor status correlates with the prognosis, it does so to a lesser degree than nodal status. Hormone receptor determination is, however, of critical importance as a predictive factor. Therefore, it determines response or lack of response of a particular therapy.

In the present study, HER-2/neu expression was significantly correlated with lymph node involvement. This is in line with a study by Tokatli et al. (16). Lymph node status is important in determining cancer staging and treatment options. It is worth noting that it is the most important factor in the prognosis of patients with breast cancer. As the number of positive axillary lymph nodes increases, survival rate decreases and relapse rate increase. Many authors demonstrated HER-2/neu expression is associated with lymph node metastasis and found that number of positive lymph nodes and HER-2/neu expression were related to prognosis (17). Correlation between HER-2/neu expression and lymph node involvement and vascular invasion has already been observed. In addition, the expression of HER-2/neu is an indicator of disease-free survival (16).

In contrary to other studies we found no correlation between tumor size and these biomakers (14, 18,19). However, our result was similar with Ariga et al. findings (10). The exact explanation for these variable results is not known, even though tumor size is one of the prognostic factors. Besides, we did not observe correlation with age that was similar with previous studies (10, 14). A study by Huang et al. showed that ER, PR and HER-2/neu expression varied with age. ER and PR status was not predicator of the HER-2/neu status in young age. However, in older women the hormone receptor status was associated with HER-2/neu (20).

In the present study, HER-2/neu expression was significantly associated with ER and PR negative status (P= 0.0001). This is similar to study by Ariga et al. (10). It has been suggested that this association may reflect a better prognosis. However, other studies revealed ER-positive, HER-2/neu-positive status accompanied by poorer survival than ER-positive, HER-2/neu-negative status (21, 22). Therefore, it seems that HER-2/neu expression is a better predicator of response to hormonal therapy than ER status alone.

Study limitations include the fact that we investigated the biomarkers status only in IDC but not in other types of breast carcinoma.

 

Conclusion

Our results showed positive correlation between ER and PR accompanied by inverse correlation of them with HER-2/neu. In addition, we found significant correlation between ER and PR positive status and low grade tumors. On the other hand, correlation between HER-2/neu and high grade tumor and lymph node involvement was significant. These findings showed the importance of these biomarkers because they provide valuable prognostic information for best therapeutic decision.

 

Acknowledgments

The authors wish to thank the personnel of Pathology Department of Shahid Beheshti Hospital for data collecting. Moreover, we thank Research Center of Shahid Beheshti Hospital for great help.

 

Conflict of interest

The authors declare that there is no conflict of interests.

How to cite this article:
Siadati S, Sharbatdaran M, Nikbakhsh N, Ghaemian N. Correlation of ER, PR and HER-2/Neu with other Prognostic Factors in Infiltrating Ductal Carcinoma of Breast. Iran J Pathol. 2015;10(3):221-6.

  1. Harirchi I, Kolahdoozan S, Karbakhsh M, Chegini S, Mohseni SM,Montazeri A et al. Twenty years of breast cancer in Iran: downstaging without a formal screening program. Ann Oncol 2011;22(1):93-7.
  2. Ghaemian N, Siadati S, Nikbakhsh N, Mirzapour M, Askari H, Asgari S. Concordance rate between fine needle aspiration biopsy and core needle biopsy in breast lesions. IJP 2013;8(4):241-6.
  3. Kolahdoozan S, Sadjadi A, Radmard AR, Khademi H. Five common cancers in Iran. Arch Iran Med 2010;13(2):143-6.
  4. Sajadi A, Nouraie M, Ghorbani A, Alimohammadian M, Malekzadeh R. Epidemiology of breast cancer in the Islamic republic of Iran: first results from a population-based cancer registry. East Medit Health J 2009;6(15):1426-31.
  5. Omranipour R, Fattahi AS. Prevalence of ductal carcinoma insitu of the breast in Tehran university cases. Tehran Univ Med J 2009;67(7):516-21.
  6. Harigopal M, Berger AJ, Camp RL, Rimm DL, Kluger HM. Automated quantitative analysis of E-cadherin expression in lymph node metastases is predictive of survival in invasive ductal breast cancer. Clin Cancer Res 2005;11(11):4083-9.
  7. Azizun-Nisa, Bhurgri Y, Reza F, Kayani N. Comparision of ER,PR and HER-2/neu (C-erb B2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer. Asian Pac J Cancer Prev 2008;9(4):553-6.
  8. Chen XS, Ma CD, Wu JY, Yang WT, Lu HF,Wu J, et al. Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer. Tumori 2010;96(1):103-10.
  9. Onoda T, Yamauchi H, Yagata H, Tsugawa K, Hayashi N, Yoshida A, et al. The value of progesterone receptor expression in predicting the recurrence score for hormone-receptor positive invasive breast cancer patients. Breast Cancer 2013;1.
  10. Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P. Correlation of Her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Breast J 2005;11(4):278-80.
  11. Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, et al. Association between tumor characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. J Clin Pathol 2005;58:611-6.
  12. Ambroise M, Ghosh M, Mallikarjuna VS, Kurian A. Immunohistochemical profile of breast cancer patients at a tertiary care hospital in South India. Asian Pac J Cancer Prev 2011;12(3):625-9.
  13. Sirati F, Ghahri A. Detection of prognostic factors in breast cancer and their relation with menopause and age. Iran J Surg 2007;15(3):41-52.
  14. Ivkovic-Kapicl T, Knezevic-Usaj S, Djilas-Ivanovic D, Panjkovic M. Correlation of Her-2/neu protein overexpression with other prognostic and predictive factors in invasive ductal breast cancer. Anticancer Res 2007;21(6):637-78.
  15. Nyagol J, Nyongo A, Byakika B, Muchiri L, Cocco M, de Santi MM, et al. Routine assessment of hormonal receptor and HER-2/neu status underscores the need for more therapeutic targets in Kenyan women with breast cancer. Anal Quant Cytol Histol 2006;28(2):97-103.
  16. Tokatli F, Altaner S, Uzal C, Ture M, Kocak Z, Uygun K, et al. Association of Her-2/neu overexpression with the number of involved axillary lmph nodes in hormone receptor positive breast cancer. Exp Oncol 2005;27(2):145-9.
  17. Mittra I, Redkar AA, Badwe RA. Prognosis of breast cancer: evidence for interaction between C-erB-2 overexpression and number of involved axillary lymph nodes. J Surg Oncol 1995;60(2):106-11.
  18.  Bhatavdekar JM, Patel DD, Shah NG, Vora HH, Suthar TP, Ghikhlikar PR, et al. Prognostic significance of immunohistochemically localized biomarkers in stage II and stage III breast cancer: a multivariate analysis. Ann Surg Oncol 2000;7(4):305-11.
  19.  Prati R, Apple SK, He I, Gornbei JA, Chanh HR. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer. Breast J 2005; 11(6):433-9.
  20. Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, et al. Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer. Ann Oncol 2005;16(11):1755-61
  21. Pinato AE, Andre S, Noberga S et al. C-erB-2 oncoprotein overexpression identifies a subgroup of estrogen receptor positive (ER+) breast cancer patients with poor prognosis. Ann Oncol 2001;12(4):525-33.
  22. Ferrero-Pous M, Hacene K, Bouchest C et al. Relationship between C-erB-2 and other tumor characteristics in breast cancer prognosis. Clin Cancer Res 2000;6(12):4745-54.